Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

LABORATORY CORPORATION OF AMERICA HOLDINGS

Filed by KELLEY DRYE & WARREN LLP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2026
Income
$110,000.00
Expenses
Not reported
Filing UUID
291ae41b-4595-4194-ae24-5a787a279fc3
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Literal federal measure citations: H.R. 5269, S. 2761, H.R. 5582, S. 2355, H.R. 9393, H.R. 8890

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.